| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Antitumor activity of thalidomide in refractory multiple myeloma.
|
N Engl J Med
|
1999
|
11.27
|
|
2
|
Apixaban in patients with atrial fibrillation.
|
N Engl J Med
|
2011
|
9.97
|
|
3
|
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
|
N Engl J Med
|
2007
|
8.77
|
|
4
|
Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study.
|
Arch Intern Med
|
2000
|
7.62
|
|
5
|
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
|
Lancet
|
2007
|
7.23
|
|
6
|
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.
|
J Clin Oncol
|
2005
|
6.98
|
|
7
|
A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group.
|
N Engl J Med
|
1999
|
6.88
|
|
8
|
Malignancies, prothrombotic mutations, and the risk of venous thrombosis.
|
JAMA
|
2005
|
6.16
|
|
9
|
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients.
|
J Thromb Haemost
|
2005
|
5.92
|
|
10
|
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.
|
Blood
|
2005
|
5.82
|
|
11
|
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.
|
N Engl J Med
|
2012
|
5.80
|
|
12
|
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.
|
Lancet Oncol
|
2009
|
5.73
|
|
13
|
American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer.
|
J Clin Oncol
|
2007
|
5.36
|
|
14
|
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.
|
Lancet
|
2006
|
5.07
|
|
15
|
Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
|
N Engl J Med
|
2013
|
4.43
|
|
16
|
Apixaban for extended treatment of venous thromboembolism.
|
N Engl J Med
|
2012
|
4.37
|
|
17
|
Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
|
Circulation
|
2004
|
3.83
|
|
18
|
Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial.
|
BMJ
|
2006
|
3.58
|
|
19
|
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
|
N Engl J Med
|
2011
|
3.30
|
|
20
|
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial.
|
Lancet
|
2010
|
3.29
|
|
21
|
Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients.
|
Blood
|
2001
|
2.82
|
|
22
|
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
|
Leukemia
|
2007
|
2.76
|
|
23
|
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.
|
Blood
|
2008
|
2.68
|
|
24
|
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
|
J Clin Oncol
|
2002
|
2.63
|
|
25
|
Thalidomide as initial therapy for early-stage myeloma.
|
Leukemia
|
2003
|
2.02
|
|
26
|
The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma.
|
Mayo Clin Proc
|
2005
|
2.00
|
|
27
|
Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study.
|
Blood
|
2010
|
1.89
|
|
28
|
Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.
|
J Clin Oncol
|
2003
|
1.87
|
|
29
|
Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.
|
Blood
|
2001
|
1.80
|
|
30
|
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
|
Blood
|
2011
|
1.76
|
|
31
|
High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study.
|
Blood
|
2010
|
1.61
|
|
32
|
Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232).
|
Blood
|
2010
|
1.55
|
|
33
|
The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide - vincristine - doxorubicin - methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysis.
|
Leuk Lymphoma
|
2006
|
1.49
|
|
34
|
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping.
|
Blood
|
2008
|
1.45
|
|
35
|
Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies.
|
Thromb Haemost
|
2010
|
1.39
|
|
36
|
First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma.
|
Haematologica
|
2004
|
1.38
|
|
37
|
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
|
J Clin Oncol
|
2011
|
1.32
|
|
38
|
Deep venous thrombosis and thalidomide therapy for multiple myeloma.
|
N Engl J Med
|
2001
|
1.32
|
|
39
|
Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis.
|
Blood
|
2006
|
1.31
|
|
40
|
Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease.
|
Cancer
|
2004
|
1.30
|
|
41
|
Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.
|
Blood
|
2002
|
1.20
|
|
42
|
Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation.
|
Br J Haematol
|
2004
|
1.14
|
|
43
|
A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer.
|
J Thromb Haemost
|
2012
|
1.10
|
|
44
|
Thalidomide and dexamethasone for resistant multiple myeloma.
|
Br J Haematol
|
2003
|
1.08
|
|
45
|
Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis.
|
J Thromb Haemost
|
2011
|
1.05
|
|
46
|
Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma.
|
Hematol J
|
2004
|
1.03
|
|
47
|
Efficacy and safety of anticoagulant prophylaxis to prevent venous thromboembolism in acutely ill medical inpatients: a meta-analysis.
|
J Intern Med
|
2008
|
1.02
|
|
48
|
Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma.
|
Clin Cancer Res
|
2002
|
1.00
|
|
49
|
Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations.
|
Thromb Haemost
|
2006
|
0.99
|
|
50
|
Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age.
|
Blood
|
2003
|
0.93
|
|
51
|
Optimal low-molecular-weight heparin regimen in major orthopaedic surgery. A meta-analysis of randomised trials.
|
Thromb Haemost
|
2003
|
0.92
|
|
52
|
Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma.
|
Ann Hematol
|
2010
|
0.92
|
|
53
|
Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma.
|
Br J Haematol
|
2009
|
0.91
|
|
54
|
Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma.
|
Haematologica
|
2006
|
0.89
|
|
55
|
Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy.
|
Leukemia
|
2004
|
0.87
|
|
56
|
Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study.
|
Ann Oncol
|
2004
|
0.87
|
|
57
|
Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis.
|
Arch Cardiovasc Dis
|
2011
|
0.84
|
|
58
|
Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide.
|
J Thromb Haemost
|
2006
|
0.81
|
|
59
|
An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment.
|
Leuk Res
|
2003
|
0.81
|
|
60
|
Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.
|
Eur J Haematol
|
2005
|
0.76
|
|
61
|
[Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors. Proposals of the Working Group on Perioperative Haemostasis (GIHP) - March 2013].
|
Ann Fr Anesth Reanim
|
2013
|
0.76
|
|
62
|
[Perioperative venous thromboembolism prophylaxis: short review and recommendations].
|
Ann Fr Anesth Reanim
|
2008
|
0.75
|